case_images: PMC7426437_01
case_images: The dynamics of the throat swab and stool sample test of SARS-CoV-2 RNA, body temperature, blood cell counts, and medications of a mild COVID-19 during hospitalization. Antiviral medication: Kaletra, Arbidol, Darunavir, and Chloroquine. Supplementary medication: Thymalfasin and IVIG. IVIG, intravenous immunoglobulin; WBC, white blood cell count (3.5-9.5 x 109/L); LYMPH, lymphocytes (1.1-3.2 x 109/L).
case_images: fimmu-11-01936-g0001.jpg
case_images: PMC7426437_01_fimmu-11-01936-g0001.jpg
case_images: F1
case_images: During hospitalization, the patient experienced an occasional cough, but his temperature and white blood cell and lymphocyte counts were normal (Figure 1, upper panel and middle panel, respectively), and his vital signs were stable. Thymalfasin and intravenous immunoglobulin were also administered to enhance immunity (Figure 1, lower panel). February 15 (23 days after onset) (Figure 1, upper panel). Four days later, the patient was discharged according to the discharge criterion.
case_images: PMC7426437_02
case_images: Serological assays of IgG and IgM specific to SARS-CoV-2 of a mild COVID-19 patient, with a severe COVID-19 case as the control. The presence and concentration of IgM and IgG targeting SARS-CoV-2 were measured using a fluorescent immunochromatography detection kit specific to the IgM and IgG against SARS-CoV-2. The cutoff values for IgG and IgM detection were 0.057 and 0.067, respectively.
case_images: fimmu-11-01936-g0002.jpg
case_images: PMC7426437_02_fimmu-11-01936-g0002.jpg
case_images: F2
case_images: IgM and IgG in the mild COVID-19 patient showed similar changes: (1) IgM was undetectable and IgG was just a little bit higher than the cutoff value on day 8 of onset; (2) their levels increased equally and seemly peaked on day 15 (with about a 6-fold increase of IgG); (3) both antibodies then decreased and remained relatively stable from day 25 after onset until discharge (Figure 2). In contrast, both the virus-specific IgM and IgG of the control patient were detected at weak levels on day 8 after onset, and then significantly increased, peaking on day 15 (with about a 15-fold increase of IgG). Noticeably, their levels were much higher than those of the mild patient in this report (Figure 2).